isoproterenol has been researched along with cicaprost in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jones, RL; Qian, YM | 1 |
| Cook, JA; Fernando, LP; Gettys, TW; Halushka, PV; Makhlouf, MA | 1 |
| Baloch, M; Clapp, LH; Hall, S; Turcato, S | 1 |
| Kinsella, BT; O'Meara, SJ | 1 |
5 other study(ies) available for isoproterenol and cicaprost
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission.
Topics: Amino Acid Oxidoreductases; Animals; Colon; Epoprostenol; In Vitro Techniques; Isoproterenol; Male; Muscle Contraction; Neural Inhibition; Nitric Oxide; Nitric Oxide Synthase; Potassium Chloride; Purinergic Agonists; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Purinergic; Synaptic Transmission; Vasoactive Intestinal Peptide | 1995 |
Increased prostacyclin and PGE2 stimulated cAMP production by macrophages from endotoxin-tolerant rats.
Topics: Adenylyl Cyclases; Animals; Blotting, Northern; Cell Membrane; Cyclic AMP; Dinoprostone; Drug Tolerance; Endotoxins; Epoprostenol; Isoproterenol; Lipopolysaccharides; Macrophages; Male; Rats; Rats, Inbred Strains; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; RNA, Messenger | 1998 |
Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost.
Topics: Animals; Antineoplastic Agents; Calcium; Dose-Response Relationship, Drug; Endothelium, Vascular; Epoprostenol; Guinea Pigs; Hydrazines; Iloprost; Isoproterenol; Male; Muscle, Smooth, Vascular; Oxazepines; Phenylephrine; Potassium Channel Blockers; Potassium Channels; Prostaglandin Antagonists; Tetraethylammonium; Vasodilation; Vasodilator Agents | 1998 |
The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
Topics: Adrenergic beta-Agonists; Alkyl and Aryl Transferases; Amino Acid Motifs; Animals; Calcium Signaling; Carrier Proteins; Cell Line; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Endocytosis; Epoprostenol; Farnesyltranstransferase; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Iloprost; Isoproterenol; Kidney; Leukemia, Erythroblastic, Acute; Mice; Mutagenesis, Site-Directed; Organophosphorus Compounds; Piperidines; Proline; Propanolamines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Receptors, Adrenergic, beta-2; Receptors, Epoprostenol; Receptors, Thromboxane A2, Prostaglandin H2; Recombinant Fusion Proteins; Signal Transduction; Transfection | 2005 |